Covered, compounding. A 1.19% yield on a $0.69 quarterly dividend, raised July 30, 2026 from $0.63 for the 21st consecutive year of growth, is covered at a 33.7% trailing payout. Sterilization and infection-prevention demand is recurring by nature, and the raise — not just the payout — is the compounding evidence.
Key risk: Acquisition execution — the $2.1 billion Xodus Medical acquisition announced in October 2026 adds debt-funded growth; integration or leverage surprises would hit the raise streak before the payout.
Changes if: Payout pushes well past 33.7% or the annual raise streak breaks. Either would end the compounding case.
- ✓Payout-coverage check: 33.7% trailing payout — $2.76 indicated against trailing earnings, leaving most profit retained.
- ✓Yield check: 1.19% indicated — $0.69/qtr × 4 at the $232.15 close on Oct. 23, 2026. Earned operating dividend, not return of capital.
- ✓Dividend growth check: 21st consecutive year of growth; latest raise +9.5%, $0.63 to $0.69, declared Jul. 30, 2026, paid Sep. 25, 2026.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.